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ABSTRACT
Background: Reduction of COL4A3, one of the six isoforms of collagen 4, in asthmatic airways results in
increased inflammation and angiogenesis, implicating it as a central part of asthma pathogenesis. However,
to date, the path underlying these diminished COL4A3 levels has been elusive. This study investigated a
possible mechanism underlying the reduction of COL4A3 expression.
Methods: Bronchial biopsies of 76 patients with asthma and 83 controls were subjected to RNA-
sequencing and DNA methylation bead arrays to identify expression and methylation changes. The
binding of ZNF263 was analysed by chromatin-immunoprecipitation sequencing coupled with quantitative
(q)PCR. Effects of ZNF263 silencing, using small interfering RNA, on the COL4A3 expression were studied
using qPCR.
Results: COL4A3 expression was significantly reduced in bronchial biopsies compared to healthy controls,
whereas DNA methylation levels at cg11797365 were increased. COL4A3 expression levels were
significantly low in asthmatics without inhaled corticosteroid (ICS) use, whereas the expression was not
statistically different between asthmatics using ICS and controls. Methylation levels at cg11797365 in vitro
were increased upon consecutive rhinovirus infections.
Conclusion: Our data indicate an epigenetic modification as a contributing factor for the loss of COL4A3
expression in asthmatic airway epithelium.
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Asthma is one of the most common lung inflammatory diseases, which significantly impairs health
throughout life, with approximately >300 million individuals worldwide affected [1]. The pathogenic
mechanisms underlying the disease are multifactorial and still not completely understood [2].
Recent evidence suggests an increasing role of epigenetics in asthma, particularly DNA methylation [3].
DNA methylation regulates gene expression by addition of a methyl group to the cytosine [4]. Along with
genetic susceptibility, exposure to allergens and tobacco smoke, repetitive human rhinovirus (HRV)
infections are considered major contributors to asthma development [5–7]. Airway constriction along with
loss of breath, wheezing, excess mucus production and airway remodelling are considered to be main
characteristics of asthma [8, 9]. Airway epithelium plays an important role by balancing immune responses
to all the various environmental and viral triggers [10]. The airway epithelium plays a critical role for
inhaler therapies such as inhaled corticosteroids (ICS) [11].
ICS are considered to be the most effective treatment for asthma to date. They are also known to reduce
the asthmatic airway inflammation [12]. Prolonged airway inflammation, one of the key asthmatic features
can result in several changes to the extracellular matrix (ECM) and can lead to pathological tissue
remodelling [13]. The ECM is the noncellular component of the lung, which includes myriad structural
components such as glycoproteins, proteoglycans and proteins, including collagens secreted by
ECM-embedded cells [14, 15].
Type IV collagen, a principal component of the basement membrane, is one of the abundant nonfibrillar
collagens in the lung [16]. There are six genes that encode for six distinct α-chains of type IV collagen
(α1–6 encoded by COL4A1-6, respectively). These α-chains form heterotrimers, which further assemble
into complex collagen networks [17, 18]. COL4A3, like all collagen type IV isoforms, is known to be
deposited as a heterotrimer in the ECM [19, 20]. Collagen type IV genes are located adjacently, orientated
in a head-to-head fashion and are transcriptionally linked in pairs, i.e. COL4A1/COL4A2, COL4A3/
COL4A4 and COL4A5/COL4A6 [21].
In the airways of high-risk wheezing asthmatic patients, collagen type IV deposition is decreased [22]. In
particular, one of the six isoforms (COL4A3) protein levels are reduced 18-fold in the lung tissue of
asthmatics [23–25]. However, the mechanism underlying reduced protein levels of COL4A3 remains
elusive. Hence, in this report, we analysed whether reduced protein expression is a result of decreased
levels of COL4A3 gene expression. Additionally, we have investigated whether an epigenetic modification is
a contributing cause of the impairment of COL4A3 expression in asthma.
Methods
Cohort
Bronchial epithelial cells biopsy cohort
Bronchial biopsies from the right lower lobe between generations three and six were collected from 76
adult patients with a prior doctor’s diagnosis of asthma [26, 27] and from 83 healthy adult control
subjects who were derived from the Normal Values of Inflammatory Variables from Healthy Subjects
study [28]. Clinical control of asthma was assessed using Asthma Quality of Life Questionnaire (AQLQ)
score [29]. All study protocols were approved by the local medical ethics committees. The ethics approval
reference number is METc 2004/271. All subjects provided written informed consent.
Cell culture
Bronchial epithelial cells-2B cell culture
Flasks were coated with fibronectin, collagen type I and bovine serum albumin. Human bronchial
epithelial cells (BEAS-2B) were cultured in bronchial epithelial cell growth medium (BEGM) medium
without gentamycin (GA)-1000 (Lonza, Switzerland) in pre-coated flasks.
Normal human bronchial epithelial cell culture
Normal human bronchial epithelial cells (NHBE) were purchased from Lonza (Switzerland) and cultured
in BEGM medium without GA-1000.
HeLA cell culture
Human cervical carcinoma cells (HeLA) were grown in Earle’s modified Eagle’s medium (EMEM)
supplemented with 2 mm L-glutamine (Lonza Group, Germany) and 10% heat-inactivated fetal bovine
serum (FBS) (ThermoFisher, USA). No antibiotics were added.
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HRV consecutive infections
BEAS-2Bs were seeded at 2×106 per T25 flask (Sarstedt, Germany) and cultured until 80% confluent. Cells
were then infected with HRV-16, at multiplicity of infection (MOI) of 0, 5 for 24 h. Obtained infected
cells were further split into two parts with 80% of cells transferred to RLT buffer (Qiagen, Hilden,
Germany) for further analysis and 20% was re-seeded for following infections. This procedure was
repeated for up to five times with a time interval of 72 h between each rhinovirus infection (RVI). Samples
were analysed after first, third and fifth infection (supplementary figure 1).
Small interfering RNA transfections
Cells were cultured at 35000 cells per well in 24-well tissue culture plate with EMEM medium
supplemented with 10% FBS before the day of transfection. 25 nM small interfering (si)RNA
(ON-TARGET; Horizon Discoveries, USA) against ZNF263 and nontarget siRNA (Horizon Discoveries,
USA) as control were delivered via transfection by means of lipofectamine 2000 (Invitrogen, Germany).
Manufacturer’s recommendations were followed. Cells were harvested 18 h post-transfection.
Genome-wide analysis of DNA methylation and RNA expression
DNA and RNA were isolated from bronchial biopsies using the AllPrep DNA/RNA/Protein Mini Kit
(Qiagen). DNA and RNA concentrations were quantified using the FLUOstar Omega-system (BMG
Labtech, Ortenberg, Germany). RNA quality was assessed by Agilent RNA6000 Nano Chip (Agilent, USA)
on an Agilent 2100 Bioanalyzer. Only samples with a RNA integrity number >8 were accepted for further
analysis by RNA-sequencing. Analysis of DNA methylation and RNA-sequencing was carried out at the
Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel (Kiel, Germany), following
the manufacturer’s protocols. The genome-wide analysis of loci-specific DNA methylation was performed
using 500 ng bisulfite-converted genomic DNA (EZ DNA methylation Kit; Zymo Research, Germany) and
the HumanMethylation450 BeadChip kit (WG-314-1003; Illumina, Germany). β-values were
Illumina-normalised (Partek Genomic Suite; Partek, USA) and categorised according to the GSE40699 and
as described by DU et al. [30]. Any β-value ⩽0.2 was considered to be fully unmethylated. β-values
between 0.2 and 0.6 were considered to be partially methylated.
For RNA sequencing, 1000 ng total RNA was processed using HiSeq PE Cluster Kit v4, cBot
(PE-401-4001; Illumina, USA), the HiSeq SBS Kit v4 (FC-401-4003; Illumina, USA) and the HiSeq2500
System (Illumina, USA). Strand-specific sequencing with 2×125 bp resulted in FASTQ data files further
processed with Partek Flow. Average read quality (Phred) was set at >20 to optimise alignment. Alignment
was performed using GSNAP (v3, 31.03.2013). All data are expressed as reads per kilobase per million
mapped reads.
Pyrosequencing
The outcome of DNA methylation quantification, cg11797365, was verified by pyrosequencing. 200 ng
DNA was converted into bisulfite DNA using EpiTect Bisulfite kit (Qiagen). Converted bisulfite DNA was
analysed further using Q24 PyroMark PCR Kit 200 (Qiagen), PyroMark Gold Reagents 5×24 Kit (Qiagen)
and PyroMark System (Qiagen). Primer pairs used for pyrosequencing are listed in supplementary table 1.
Chromatin-immunoprecipitation DNA-sequencing
Chromatin-immunoprecipitation sequencing (ChIP-seq) was performed by Active Motif (Carlsbad, USA).
Concisely, the zinc finger protein 263 (ZNF263) ChIP-quantitative (q)PCR assay was performed using
30 μg BEAS-2B and NHBE chromatin and 5 μL antibody against ZNF263 (Novus Biologicals, Germany).
Differential ZNF263 quantification results were verified using qPCR on three validation sites (COL4A3,
AHDC1, AP1S3) around the region of interest and a positive control pair (ANO7). Untr4, an
untranscribed genomic region on human chromosome 4 is used as a negative control primer pair. The
primers used are listed in supplementary table 2.
qPCR
As mentioned earlier, total RNA was isolated following manufacturer’s protocol and cDNA was
synthesised using Superscript VILO cDNA synthesis kit (Invitrogen). Pre-designed prime-time qPCR
assays for ZNF263 (Hs.PT.58.19342521), COL4A3 (Hs.PT.249834) and GAPDH (Hs.PT.39a.22214836)
were used (IDT Technologies, the Netherlands). qPCR was performed using Taq-Man PCR master mix
(Life Technologies, Carlsbad, USA) on a Bio-Rad Applied Biosystems 7900 HT Fast real-time PCR system
(Thermo-Fisher Scientific, Waltham, USA). We used the 2−ΔΔct method to quantify the relative RNA
expression level using glyceraldehyde 3-phosphate dehydrogenase as an endogenous reference. Three
independent experiments were conducted with a minimum of three replicates per experiment.
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Data analysis
The datasets of DNA methylation and RNA expression were normalised before analysis. For both datasets,
the software package Partek Genomic Suite was used to detect differentially methylated CpGs as well as
differentially expressed RNA. Resulting CpG sites were checked for known single nucleotide
polymorphisms (SNPs). Statistical analysis was performed using JMP13 (SAS, USA) and Prism 6
(GraphPad, USA). Data were statistically analysed with a nonparametric Kruskal–Wallis with Dunn’s
post-test and Mann–Whitney U-test where appropriate.
Results
Study population
The cohort consisted of 159 subjects, of whom 83 were healthy. Among healthy controls, 38 (45.8%)
subjects were female. Mean (range) age of controls was 46 (18–73) years. 76 subjects of the cohort had
doctor-diagnosed asthma, of whom 38 (50%) patients were female. Among asthmatic patients, 50 were ICS
users and 26 were not using ICS (table 1). Patients in the ICS group were receiving beclomethasone
equivalent to 800 µg·day−1 (200–1000 µg·day−1).
Control of asthma was assessed using the AQLQ in 76 patients, of whom 15 (32.8%) were well controlled,
six (7.8%) were totally controlled and 28 (36.8%) were not controlled; the asthma control status of 15
patients was not available and two patients were not evaluated.
COL4A3 expression reduction in asthma is associated with use of ICS and increased levels of
DNA methylation at cg11797365
Aiming to investigate whether decrease of COL4A3 gene expression is causative for the previously found
reduced COL4A3 protein levels [24], we analysed COL4A3 gene expression in bronchial biopsies (table 1)
using RNA-seq. Overall expression levels of COL4A3 were significantly reduced in asthmatics (fragments
per kilobase per million mapped reads (FPKM) 0.68±0.05, n=76) when compared to controls without
respiratory disease (FPKM 0.81±0.04, n=83) (p<0.01; figure 1a). COL4A3 expression was found to be
independent of sex (supplementary figure 2A), age, weight, atopy or use of ICS in a univariate analysis
(supplementary table 3). Using a multivariant regression, COL4A3 expression correlated with diseases
status and sex but not age, weight, atopy or use of ICS (supplementary table 4). Corticosteroids are known
to have an effect on gene expression and glucocortico-response elements are present in the promotor
region of COL4A3 [31, 32]. Furthermore, treatment with 100 nM dexamethasone in BEAS-2B cells in vitro
for 24 h showed a significant ∼3.75-fold increase in COL4A3 transcripts compared to basal expression
levels (supplementary figure 2B, p<0.01). Hence, we compared the COL4A3 expression levels in the cells of
asthmatics from our bronchial epithelial cells biopsy cohort, either using ICS or not. COL4A3 expression
levels were found to be significantly low in asthmatics without ICS use (figure 1b; p<0.01), whereas the
expression was not found to be statistically different between asthmatic patients using ICS and controls.
We reasoned that a possible mechanism for the decreased expression could be an altered gene regulation
via SNPs or epigenetic modifications. The altered gene regulation was found not to be associated with any
reported SNPs (data not shown). Hence, a comparative analysis of the DNA methylation sites in bronchial
biopsies was performed. We identified one DNA methylation site, cg11797365, which is located in the first
intron, having significantly higher methylation in asthmatic patients (table 2). This finding was
independent of sex or age in our cohort (supplementary figures 2C and D).
TABLE 1 Bronchial epithelial cell biopsy cohort
Controls Asthma
ICS No ICS
Subjects n 83 50 26
Age# years 46 48.6** 46.3
Female# % 45.8 54 42.3
FEV1
# % pred 100 82**** 83****
BMI kg·m−2 23.6 27*** 27***
ICS dose µg·day−1 NA 800 (200–1000) NA
FEV1: forced expiratory volume in 1 s; BMI: body mass index; ICS: inhaled corticosteroids (dose equivalent
to beclomethasone); NA: not applicable. #: mean values. **: p<0.01, ***: p<0.001, ****: p<0.0001, asthma
versus controls.
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Stratifying for ICS use, cg11797365 was significantly increased in asthmatic patients without ICS use as
compared to controls (figure 1c; p<0.05). No significant difference was found between ICS users and
healthy controls (figure 1c, supplementary table 5). To explore a possible regulatory function of
cg11797365 on COL4A3 expression, we grouped subjects into low methylated and medium methylated
levels at cg11797365 according to the β-value (<0.2; cut-off values described in the materials and methods
section). Expression of COL4A3 remained significantly reduced in low-methylated asthmatics with no ICS
use as compared to controls (figure 1d; p<0.05). In patients with medium methylated levels at cg11797365
(β-value ⩾0.2), expression levels of COL4A3 did not change regardless of the ICS usage (supplementary
figure 2E). This may suggest that medium methylation at cg11797365 alters the transcriptional response of





































































FIGURE 1 COL4A3 expression reduction in asthma is associated with use of inhaled corticosteroids (ICS) and
increased levels of cg11797365 methylation. a) Expression of COL4A3 in controls (n=83) and asthmatics (n=76)
(Mann–Whitney U-test, **: p<0.01). b) Expression of COL4A3 in controls (n=83), patients with asthma using ICS
(n=50) and not using ICS (n=26) is significantly reduced in the latter (Kruskal–Wallis with Dunn’s post-test,
**: p<0.01 compared to controls). c) Methylation (β-value) of cg11797365 in asthmatic ICS users and non-
users as compared to control subjects (Kruskal–Wallis with Dunn’s post-test, *: p<0.05 compared to control
subjects). d) COL4A3 expression in control and asthmatic subjects with low methylation (β-value <0.2); healthy
controls n=59, patients with asthma using ICS n=33 and not using ICS n=19 (Kruskal–Wallis with Dunn’s
post-test *: p<0.05 compared to control subjects). Data are presented as mean±SEM. RPKM: kilobase per
million mapped reads; FPKM: fragments per kilobase per million mapped reads; NS: nonsignificant.
TABLE 2 Change of level of DNA methylation in bronchial biopsies isolated from bronchial epithelial cell biopsy cohort: asthma
versus controls
Current asthma Control p-value
Methylation β-value Patients Methylation β-value Patients
cg27243623 0.455±0.073 70 0.479±0.068 70 0.041
cg11797365# 0.177±0.041 70 0.165±0.034 70 0.045
cg04324308 0.081±0.031 70 0.075±0.009 70 0.088
cg12349837 0.697±0.084 70 0.717±0.074 70 0.129
cg19865525 0.084±0.027 70 0.087±0.027 70 0.388
cg08280392 0.111±0.018 70 0.113±0.020 70 0.681
cg22994281 0.072±0.013 70 0.072±0.011 70 0.929
Data are presented as mean±SD or n, unless otherwise stated. #: site with increased methylation levels in asthmatic patients.
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Increased DNA methylation at site cg11797365 interrupts ZNF263 binding, leading to reduced
COL4A3 expression
Through analysis of publicly available data (www.genome.ucsc.edu) we identified cg11797365 to be located
in close proximity (five base pairs downstream towards the 3′-end) to the consensus motive TcCTCCc for
a confirmed transcription factor, ZNF263 binding site in the first intron of the COL4A3 gene. ChIP-seq
analysis carried out in NHBE cells confirmed the binding of ZNF263 in the first intron of the COL4A3
gene (figure 2a). This quantitative analysis revealed that ZNF263 bound less to the intronic COL4A3
region in NHBE cells which exhibited increased methylation of 10.7% at cg11797365 as compared to
BEAS-2B with methylation of 6.4% (p<0.05; figure 2b, supplementary table 6). To prove the enhancing
function of ZNF263, we analysed COL4A3 mRNA expression in HeLa cells transfected with siRNA
targeting ZNF263. Silencing of ZNF263 was associated with a significant reduction of COL4A3 mRNA
expression in siRNA-transfected HeLa cells (figure 2c and d). Our data indicate that a significant increase
in DNA methylation levels at cg11797365 is present in asthmatics. Reduced COL4A3 expression in
asthmatics is likely mediated by abrogated transcriptional control at cg11797365, possibly exerted via
decreased binding of the transcription factor ZNF263. We have further analysed the impact of ICS on
ZNF263 expression in our bronchial biopsies samples stratified for ICS use. No significant impact of ICS
use on ZNF263 expression (supplementary figure S4) has been found, which suggests that the effect of ICS
is not associated with ZNF263 expression in asthmatic patients.
RVI induces increased DNA methylation levels at cg11797365 in vitro
It was recently reported that RVI can induce DNA methylation changes in nasal epithelial cells in vitro
[33, 34]. However, the consequences of consecutive RVIs on the COL4A3 DNA methylation levels are not
fully understood. To outline the effects of RVIs on genome-wide methylation in epithelial cells, we





























































































FIGURE 2 ZNF263 binding is interrupted in asthmatic patients due to increased methylation at site cg11797365 leading to a reduced COL4A3
expression. a) Detection hits of chromatin-immunoprecipitation sequencing (ChIP-seq) data of ZNF263 in COL4A3 region. Large peak corresponds
to region of first exon and start of first intron. cg11797365 is indicated by the red arrow and corresponds with previous report on ZNF263 binding
(ENCODE track). The methylation site cg11797365 is close to the consensus binding site (green highlight in ENCODE track) of ZNF263. Custom
track from ChIP-seq data from normal human bronchial epithelial cells (NHBE) is shown as indicated. b) Quantitative ChIP-seq analysis of
ZNF263 binding to genomic region COL4A3 (1. intron) of cg11797365 in human bronchial epithelial cells (BEAS-2B) and NHBEs. Normalised
binding events (per 1000 cells), n=4 per cell line (BEAS-2B and NHBE; Lonza). c) Quantitative (q)PCR to quantify ZNF263 expression levels in HeLA
cells transfected with small interfering (si)RNA against ZNF263 in comparison to cells transfected with a nontarget control. d) Expression of
COL4A3 in HeLA cells transfected with siRNA against ZNF263 compared to cells transfected with a nontarget control. Δct values are normalised to
GAPDH. *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001, Mann–Whitney U-test.
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methylation 450k chips. Consecutive RVIs significantly altered levels of methylation in 33826 CpGs
(figure 3a; linear regression false discovery rate corrected p<0.01), out of which 17 methylation sites were
found to be located on COL4A3. To understand the consequences of consecutive RVIs on COL4A3
methylation and expression, we quantified DNA methylation and gene expression levels of COL4A3 in
BEAS-2B cells by pyrosequencing and qPCR, respectively. 15 out of the 17 DNA methylation sites from
the 450k chips in COL4A3 were significantly associated (p<0.05) with either the number of infections, the
viral titre (MOI) or the duration of the in vitro infection (table 3). Of the 15 methylation sites investigated,
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FIGURE 3 Methylation levels at cg11797365 are increased, expression levels of COL4A3 are decreased after
consecutive rhinovirus infections (RVI) in vitro. a) Hierarchical clustering heat map (Ward’s minimum variance)
of genome-wide methylation changes after consecutive numbers of infections with human rhinovirus-16
(p<0.01, false discovery rate adjusted linear regression p-values). All methylation levels are normalised.
b) Methylation level at site cg11797365 increased significantly after RVI. Levels of methylation after each RVI
were compared to no RVI (n=4; 1 RVI n=10, 3 RVI n=4, 5 RVI n=4). c) COL4A3 expression (reads per kilobase
per million mapped reads (RPKM)) decreases after each RVI (no RVI n=4; 1 RVI n=10, 3 RVI n=4, 5 RVI n=4).
Data are presented as mean±SEM. *: p<0.05, **: p<0.01 by Kruskal–Wallis with Dunn’s post-test.
TABLE 3 Effects of rhinovirus infection on DNA methylation levels of different CpGs in the
COL4A3 gene
Form of infection Log-worth# p-value
cg08280392 DOI 2.62 0.0024
cg19865525 DOI 1.399 0.03987
cg27243623 DOI 2.593 0.00255
cg22994281 DOI 1.805 0.01566
cg04324308 DOI 3.407 0.00039
cg11797365¶ DOI*NOI 3.89 0.00013
cg13951042 DOI*NOI 3.462 0.00035
cg27243623 DOI*NOI 2.193 0.00641
cg22994281 DOI*NOI 1.473 0.03368
cg04324308 DOI*NOI 2.175 0.00668
cg12349837 MOI 2.547 0.00284
cg19865525 MOI 1.332 0.04655
cg08280392 MOI*NOI 1.744 0.01802
cg27243623 MOI*NOI 4.009 0.0001
cg12349837 NOI 3.616 0.00024
DOI: duration of infection (4 h, 24 h, 48 h); NOI: number of consecutive infections (0, 1, 3, 5); MOI:
multiplicity of infection (number of virus particles per cell); DOI*NOI, MOI*NOI: combination effect of DOI
and NOI, MOI and NOI determining increase of methylation. #: log-worth: −log10(p-value); ¶: site with
increased methylation levels in asthmatic patients .
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DNA methylation levels at cg11797365 significantly increased with successive numbers of infections
(p<0.05; figure 3b), whereas RNA-seq analysis revealed a significantly decreased COL4A3 expression upon
successive numbers of infections (figure 3c; five consecutive infections versus no infection, p<0.01). The
expression level was also confirmed by qPCR (supplementary figure 4). These findings suggest that
consecutive RVI in vitro increased methylation levels at cg11797635 within the COL4A3 gene, while being
associated with decreased levels of gene expression in BEAS-2B cells.
COL4A3 expression and DNA methylation at cg11797365 are independently associated with
asthma and correlate with lung function
To better understand the association of cg11797365 methylation and COL4A3 expression level with
asthma, we combined our data with the dataset from NICODEMUS-JOHNSON et al. [35] (GSE85568) to 207
matched DNA methylation and expression pairs. COL4A3 expression levels were z-transformed and
β-values of DNA methylation levels were used without additional transformation. To compensate dataset
inherent variations, a variable “dataset” was used in our logistic regression analysis. We did not find a
direct association of gene expression and levels of DNA methylation in the combined dataset (p=0.832;
supplementary table 7). Next, we performed a logistic regression analysis for both variables for asthma
outcome. We included age, sex, β-values of cg11797365, z-values of COL4A3 expression and the dataset.
Logistic regression returned a significant and independent association for age (p=0.0072), cg11797365
(p=0.0254), z-value (COL4A3) (p=0.0498) and dataset (p=0.001), but not for sex (p=0.0624)
(supplementary table 8).
Additionally, better lung function (forced expiratory volume in 1 s (FEV1) % predicted) was associated
with higher COL4A3 expression (Spearman correlation coefficient rs=0.23, p=0.02; figure 4c) in controls
and asthmatic patients who did not receive ICS. However, no correlation was found in patients after ICS
treatment (data not shown). Furthermore, higher levels of methylation at cg11797365 correlated with
lower lung function (FEV1 % pred) in asthmatics regardless of ICS use (Spearman correlation coefficient











































FIGURE 4 Association of COL4A3 expression and methylation level at cg11797365 with lung function.
a) Spearman correlation plot of logarithmic transformed (natural logarithm) forced expiratory volume in 1 s
(FEV1) % predicted and COL4A3 expression. Correlation includes controls and asthmatic patients without
inhaled corticosteroids. rs=0.23, p=0.02, n=101. Line indicates correlation. b) Spearman correlation plot of
logarithmic transformed (natural logarithm) FEV1 % predicted and methylation levels at cg11797365 (β-value,
age- and sex-adjusted). Correlation includes patients with asthma with and without ICS. rs=−0.24, p=0.05,
n=70. Line indicates correlation.
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rs=−0.24, p=0.05; figure 4d). These results may suggest that COL4A3 expression and DNA methylation are
independently associated with asthma.
Discussion
To the best of our knowledge, our study is the first to analyse COL4A3 expression levels and report a possible
role of altered DNA methylation site which is located in COL4A3. Since our first report of an 18-fold
reduction of COL4A3 expression in asthmatic airways, the fate of COL4A3 has remained elusive [24]. Loss of
COL4A3 in asthmatic airway sections has been linked to the pathogenesis of asthma by aggravating
inflammation, mucus production, angiogenesis, goblet-cell hyperplasia, neutrophil migration and increased
bronchial hyperreactivity [23, 25, 36]. Here we shed light on decreased mRNA expression of COL4A3 and an
increased intragenic DNA methylation in asthmatics. Furthermore, our study also demonstrates the
association of ICS treatment with COL4A3 expression and DNA methylation levels at cg11797365. We
explored the loss of COL4A3 protein expression as a consequence of decreased COL4A3 gene expression.
In our study, expression of COL4A3 in bronchial biopsies from asthma patients was found to be
significantly reduced when compared to controls. We identified an intronic DNA methylation site,
cg11797365, to be significantly increased in asthmatics. Our analysis suggests an association between
increased levels of DNA methylation at cg11797365 and decreased COL4A3 expression. Furthermore, in
our cohort stratified for different levels of DNA methylation at cg11797365 (low and medium levels),
usage of ICS resulted in increased levels of COL4A3 in asthmatics with low levels of DNA methylation,
whereas expression levels of COL4A3 were found to be almost similar irrespective of the use of ICS in
asthmatics with medium levels of DNA methylation. This may suggest that medium methylation levels at
cg11797365 might alter the transcriptional response to ICS in asthmatics.
The second aim of our study was to observe if DNA methylation level and the gene expression are
associated with asthma. It has been shown that increased methylation level at cg11797365 is correlated
with decreased expression level of COL4A3 [37]. In addition, NICODEMUS-JOHNSON et al. [35] reported a
wide-ranging set of Illumina DNA-methylation array (GSE85568) and RNA-seq data (GSE85567)
generated from freshly isolated asthmatic and healthy endobronchial airway epithelial cells. In addition,
their comprehensive dataset indicated that cg11797365 was significantly increased in asthmatics and the
pathway analysis revealed that type IV collagen gene family was associated with a “tumour necrosis factor
remodelling-centred endotype”. This endotype was strongly associated with asthma severity, ICS use and
bronchoalveolar lavage eosinophil counts. This is in line with current literature in which COL4A3 is
important in reducing aggravated airway inflammation (i.e. eosinophilic, neutrophilic) and goblet cell
hyperplasia, as well as airway smooth muscle cell ECM remodelling [25, 36]. Mechanistically, we found
that an increase in DNA methylation levels at cg11797365 was responsible for a decreased binding of the
expression enhancer ZNF263. FRIETZE et al. [38] identified ZNF263 to have repressive functions in
promotor regions, but did not fully exclude the possibility of an additional enhancer function.
Furthermore, ZNF263 exhibited an enhancing effect on members of the “cellular component organisation
and biogenesis” family, to which type IV collagens belong [38]. We observed that silencing ZNF263 upon
siRNA transfection was associated with a significant reduction of COL4A3 mRNA expression. This is
supportive of our hypothesis that the reduced levels of COL4A3 expression is a consequence of decreased
binding of ZNF263. Our results imply that epigenetic modifications in COL4A3 may have a detrimental
impact on ECM homeostasis in the lung. This may suggest that DNA methylation and gene expression to
be independent variables for asthma prediction, yet the additional mechanistic factors regulating COL4A3
expression require further research.
RVIs have been shown to affect epigenetic markers such as DNA methylations in asthma-relevant genes,
especially the host immune responsive genes to HRVs such as (HLA-B)-associated transcript 3 (BAT3),
neuraminidase 1 (NEU-1) and Mothers against decapentaplegic homologue 3 (SMAD3), a susceptible
signalling intermediator activated by transforming growth factor-β in asthma [33, 39]. These findings
suggest that RVIs influence DNA methylation and are considered an additional risk factor for asthma
patients. Consistently, we found that consecutive RVIs in BEAS-2Bs led to an increased methylation at
cg11797365, while COL4A3 expression is reduced, suggesting that persistent RVIs may contribute to the
severity, and potentially the progression of asthma by affecting abundance of protein levels of COL4A3 in
bronchial airways. However, further work is warranted to understand how consecutive RVIs can lead to an
increased DNA methylation at site cg11797365 in COL4A3 in human airway epithelium.
Impairment of lung function is a key feature of asthma [40]. We postulated whether DNA methylation at
cg11797365 and/or COL4A3 expression levels are associated with lung function in patients from our
cohort. We found that higher levels of COL4A3 expression in controls and asthmatics who are not
receiving ICS was associated with better lung function. Furthermore, higher levels of DNA methylation at
cg11797365 correlated with lower lung function in asthmatics regardless of their ICS use. These results
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may suggest that COL4A3 expression and methylation levels at cg11797365 are both implicated in lung
function in healthy and asthmatics. However, further studies are required to validate our findings in a
larger cohort.
The major limitation of our study is an insufficient number of medium-methylated subjects (n=16) in our
cohort, when compared to the number of low-methylated subjects (n=111). Investigating more subjects
with medium methylation in the future to be comparable with low methylated subjects would be necessary.
BEAS-2B cells have low DNA methylation levels as compared to NHBEs. Additionally, BEAS-2Bs have the
ability to maintain their expansion capabilities even with high number of passages. Thus BEAS-2Bs proved
the best fit for our experiments in order to study DNA-methylation increase after consecutive RVIs.
Unfortunately, we were not successful in achieving comparable levels of DNA methylation at cg11797365
as seen in our human data. Lastly, we cannot exclude the possibility of carry-over of RV16 in our
consecutive infections experiment, as the viral titre was not analysed in the supernatant. Yet, we detected
no mRNA and protein expression of interleukin (IL)-6 and IL-8, chemokines which are known to be
specifically induced by RVIs, in our re-cultured but noninfected cells [33, 41]. Although RV16 carry-over
cannot be completely eliminated, the impact of any such carry-over would be minimal.
Taken together, our data provide evidence that epigenetic changes in COL4A3 may lead to a change in the
expression of COL4A3 in the bronchial airways of asthmatic patients. Usage of ICS leads to increase in
COL4A3 expression levels; however, this effect was only observed in asthma patients with low DNA
methylation levels at cg11797365, while ICS usage had no effect on COL4A3 expression levels in patients
with medium levels of DNA methylation at cg11797365. We postulate that ZNF263 binds to COL4A3 and
acts as a gene expression enhancer, while DNA methylation at cg11797365 in COL4A3 prevents the
binding and reduces the gene expression. Additionally, our findings may suggest that risk factors like RVIs
might modify the DNA-methylation of COL4A3, which leads to worse disease outcome (e.g. lung
function). Our findings suggest that patients with a DNA methylation level similar to healthy controls
would respond to ICS and benefit. When medium levels of DNA methylation at cg11797365 are present,
our data suggest that ICS treatment did not modulate COL4A3 expression, and the efficacy of ICS was
found to be less than in patients with low levels of DNA methylation at cg11797365. However, further
work is necessary to validate our findings in a larger cohort.
Collectively, based on our data, COL4A3 expression and DNA methylation are both associated with
asthma and COL4A3 can be recognised as an important molecular player in asthma.
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